Telix Pharmaceuticals Limited (TLPPF)
USD 15.71
(0.0%)
USD 15.71
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 15.84 Million AUD | 155.87% |
| 2022 | -92.2 Million AUD | -22.54% |
| 2021 | -75.24 Million AUD | -60.92% |
| 2020 | -46.76 Million AUD | -62.85% |
| 2019 | -28.71 Million AUD | -83.07% |
| 2018 | -15.68 Million AUD | -146.32% |
| 2017 | -6.36 Million AUD | -21125.71% |
| 2016 | -30 Thousand AUD | 74.14% |
| 2015 | -116 Thousand AUD | 0.0% |
| 2000 | -994 Thousand AUD | -71.97% |
| 1999 | -578 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 31 Million AUD | 0.73% |
| 2024 Q2 | 13.47 Million AUD | -31.99% |
| 2023 FY | 51.51 Million AUD | 155.87% |
| 2023 Q3 | 10.17 Million AUD | -67.62% |
| 2023 Q2 | 31.43 Million AUD | 662.2% |
| 2023 Q4 | 20.07 Million AUD | 97.22% |
| 2023 Q1 | -5.59 Million AUD | 42.37% |
| 2022 Q3 | -5.31 Million AUD | 91.63% |
| 2022 Q4 | -9.7 Million AUD | -82.58% |
| 2022 FY | -92.2 Million AUD | -22.54% |
| 2022 Q1 | -31.73 Million AUD | 36.42% |
| 2022 Q2 | -63.49 Million AUD | -100.06% |
| 2021 Q4 | -49.91 Million AUD | -100.0% |
| 2021 Q3 | -24.95 Million AUD | 21.02% |
| 2021 FY | -75.24 Million AUD | -60.92% |
| 2021 Q2 | -31.6 Million AUD | -101.72% |
| 2021 Q1 | -15.66 Million AUD | 46.25% |
| 2020 Q3 | -14.57 Million AUD | 27.53% |
| 2020 FY | -46.76 Million AUD | -62.85% |
| 2020 Q4 | -29.14 Million AUD | -100.0% |
| 2020 Q2 | -20.1 Million AUD | -100.0% |
| 2020 Q1 | -10.05 Million AUD | 58.23% |
| 2019 Q3 | -12.03 Million AUD | 25.64% |
| 2019 FY | -28.71 Million AUD | -83.07% |
| 2019 Q4 | -24.07 Million AUD | -100.0% |
| 2019 Q1 | -8.09 Million AUD | 5.84% |
| 2019 Q2 | -16.18 Million AUD | -100.0% |
| 2018 Q3 | -8.59 Million AUD | -64.34% |
| 2018 Q4 | -8.59 Million AUD | 0.0% |
| 2018 FY | -15.68 Million AUD | -146.32% |
| 2018 Q1 | -5.22 Million AUD | -111.6% |
| 2018 Q2 | -5.22 Million AUD | 0.0% |
| 2017 FY | -6.36 Million AUD | -21125.71% |
| 2017 Q4 | -2.47 Million AUD | 0.0% |
| 2017 Q3 | -2.47 Million AUD | -213.52% |
| 2017 Q1 | -788.27 Thousand AUD | 0.0% |
| 2017 Q2 | -788.26 Thousand AUD | 0.0% |
| 2016 FY | -30 Thousand AUD | 74.14% |
| 2015 FY | -116 Thousand AUD | 0.0% |
| 2000 FY | -994 Thousand AUD | -71.97% |
| 1999 FY | -578 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 122.066% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -222.291% |
| SQZ Biotechnologies Company | -75.82 Million USD | 120.89% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 188.754% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 80.648% |
| Mesoblast Limited | -84.14 Million USD | 118.824% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 1131.217% |
| Genus plc | 6.4 Million USD | -147.5% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -62.587% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 1800.702% |
| Marizyme, Inc. | -34.08 Million USD | 146.47% |
| ContraFect Corporation | -56.88 Million USD | 127.844% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 289.701% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 447.771% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 1229.822% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 655.691% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 675.824% |
| MultiCell Technologies, Inc. | -722.81 USD | 2191547.268% |
| Accustem Sciences Inc. | -3.74 Million USD | 522.804% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 126.852% |
| EV Biologics, Inc. | -483.06 Thousand USD | 3379.082% |
| Q BioMed Inc. | -3.44 Million USD | 559.715% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -347.458% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 4166.022% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 702.849% |
| Biomind Labs Inc. | -1 Million USD | 1668.934% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 424.62% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 338.267% |
| Skye Bioscience, Inc. | -13.67 Million USD | 215.859% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 897.391% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 52984.615% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 414.006% |
| IMV Inc. | -38.67 Million USD | 140.96% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 199.813% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 919.617% |
| GB Sciences, Inc. | -1.42 Million USD | 1215.093% |
| Alpha Cognition Inc. | -9.7 Million USD | 263.205% |
| HST Global, Inc. | -140.9 Thousand USD | 11341.457% |
| CSL Limited | 3.7 Billion USD | 99.572% |
| Halberd Corporation | -75.05 Thousand USD | 21205.929% |
| Enzolytics Inc. | -2.14 Million USD | 837.156% |
| Resverlogix Corp. | -12.74 Million USD | 224.245% |
| Affymax, Inc. | -15.04 Million USD | 205.277% |
| SYBLEU INC | -149.18 Thousand USD | 10718.045% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 599.957% |
| argenx SE | -425.04 Million USD | 103.727% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 128.536% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 1617.241% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 1102.941% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 565.201% |
| AVAX Technologies, Inc. | 6.69 Million USD | -136.669% |
| Zenith Capital Corp. | -8.94 Million USD | 277.122% |
| Genscript Biotech Corporation | -415.79 Million USD | 103.81% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 91024.746% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 745.131% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 9335.638% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 128.814% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 645.972% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 1709.669% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 949.617% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 1361.146% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 890.121% |
| BioStem Technologies, Inc. | -7.77 Million USD | 303.626% |
| ONE Bio Corp. | 13.68 Million USD | -15.776% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 8827.994% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 1286.134% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 1508.118% |
| Agentix Corp. | -1.37 Million USD | 1254.724% |
| LadRx Corporation | -3.82 Million USD | 514.266% |
| Cell Source, Inc. | -4.32 Million USD | 466.213% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 3912.467% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 2405.845% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 2405.845% |
| NovAccess Global Inc. | -2.46 Million USD | 742.138% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 642.569% |
| Itoco Inc. | -919.14 Thousand USD | 1823.35% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 473.725% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 1515.55% |
| Kadimastem Ltd | -3.04 Million USD | 621.01% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 6152.131% |
| CytoDyn Inc. | -18.05 Million USD | 187.717% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 63032.062% |
| Mobile Lads Corp. | -554.55 Thousand USD | 2956.37% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 7297.448% |
| Qrons Inc. | -643.67 Thousand USD | 2560.862% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 2904.915% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 810.352% |
| Rebus Holdings, Inc. | -664 Thousand USD | 2485.542% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 972.093% |
| International Stem Cell Corporation | -663 Thousand USD | 2489.14% |
| Bioxytran, Inc. | -3.82 Million USD | 514.644% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 30191.185% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 77976.106% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 143.677% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 1078.986% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 2252.657% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 609.161% |
| Neutra Corp. | -229.48 Thousand USD | 7002.382% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 190.313% |
| PureTech Health plc | -146.19 Million USD | 110.835% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 173.705% |
| IXICO plc | -1.43 Million USD | 1202.296% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 266.895% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 113.004% |
| CSL Limited | 3.81 Billion USD | 99.584% |
| Cellectis S.A. | -108.85 Million USD | 114.551% |